InFlectis BioScience: InFlectis BioScience Awarded $943,000 Grant from the ALS Association to Advance Ongoing ALS Clinical Trial with the Support of IRCCS Carlo Besta Neurological Institute

InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has been awarded a $943,000 grant to support recruitment and to investigate biomarkers in its Phase 2 clinical trial in patients with bulbar-onset ALS (NCT05508074).